Cadrenal Therapeutics' SEC filings document the regulatory record of a Nasdaq-listed, emerging-growth biopharmaceutical company focused on immune, thrombotic, and anticoagulation-related disorders. Its 8-K reports disclose financial results, Regulation FD updates, clinical and regulatory events for CAD-1005, and scientific research involving 12-lipoxygenase inhibition.
The filings also cover capital-structure activity, including common-stock registrations, at-the-market offering materials, registered direct offerings, private-placement warrants, and related material agreements. Company disclosures identify its Delaware corporate status, Nasdaq Capital Market common stock listing, governance status as an emerging growth company, and formal reporting of pipeline developments involving CAD-1005, tecarfarin, and frunexian.
On August 11, 2025, Cadrenal Therapeutics, Inc. filed a Form 8-K reporting that it issued a press release containing financial information for the fiscal quarter ended June 30, 2025, furnished as Exhibit 99.1 to the report. The filing identifies the company as an emerging growth company and shows its common stock is listed on the Nasdaq Capital Market under the symbol CVKD. The filing also furnishes the cover page interactive XBRL as Exhibit 104 and was signed by Quang X. Pham, Chairman and Chief Executive Officer.
The company states the press release and Item 2.02 disclosure are furnished, not "filed" for purposes of Section 18, and will not be incorporated by reference into other SEC filings.
Cadrenal Therapeutics (CVKD) reported unaudited results for the quarter ended June 30, 2025 showing a quarterly net loss of $3.67 million and a six‑month net loss of $7.51 million. Cash and cash equivalents were $5.57 million at June 30, 2025 and approximately $5.0 million as of August 6, 2025, which the company states is expected to fund operations for at least the next twelve months from the filing date. Working capital was about $4.3 million and the accumulated deficit stood at $33.2 million. As of August 11, 2025, there were 2,046,854 shares outstanding.
Operating expenses increased year‑over‑year: six‑month general and administrative expenses rose to $4.91 million (110% increase) and research and development expenses rose to $2.75 million (46% increase) driven by CMC, personnel and clinical preparation costs. Financing activity included $3.35 million gross ATM proceeds in H1 2025 and an additional ~$516,000 gross via ATM in July 2025. Tecarfarin holds orphan and fast‑track designations for specified indications and the company announced clinical trial initiation plans for ESKD patients transitioning to dialysis on August 5, 2025.